Covid 19 Clinical Trial
Official title:
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium
The COVID-19 outbreak is associated with a surge in ICU bed requirement and substantial mortality (estimated between 0.5% and 1%). Admission in the intensive care unit (ICU) and need for mechanical ventilation is reportedly associated with an estimated hospital mortality of more than 30%. Furthermore, the surge in ICU bed requirement is a worldwide-shared issue, leading to sub-optimal ICU management. In acute respiratory failure due to COVID-19-related pneumonia, vasoplegia with vascular enlargement inside the lung lesions and dilation of small vessels seen on chest CT scan largely account for severe hypoxemia whose physiological response is hyperventilation leading to hypocapnia. Almitrine, initially described to reduce intrapulmonary shunt by enhancement of hypoxic pulmonary vasoconstriction in combination with inhaled nitric oxide (iNO), redistributes pulmonary blood flow from shunt areas to lung units with normal ventilation/perfusion (VA/Q) ratio. Low dose of intravenous almitrine (2 µg.kg-1.min-1) alone also improves oxygenation (without combination with iNO) by selective pulmonary vasoconstriction of precapillary pulmonary arteries perfusing lung areas exposed to a hypoxic challenge with a slight increase in mean arterial pulmonary. Therefore, our hypothesis is that 5 days of low dose of almitrine therapy may improve the ventilation-perfusion (VA/Q) ratio at a relatively early stage of this specific lung disease and limit respiratory worsening and subsequent need for mechanical ventilation.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04333732 -
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
|
Phase 3 | |
Terminated |
NCT04435795 -
Inhaled Ciclesonide for Outpatients With COVID19
|
Phase 2/Phase 3 | |
Completed |
NCT04357444 -
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
|
Phase 2 | |
Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
Not yet recruiting |
NCT05052320 -
Audiological Assessment of Recovered Covid 19 Subjects.
|
||
Withdrawn |
NCT04426344 -
Core Warming of COVID-19 Patients
|
N/A | |
Recruiting |
NCT05595031 -
Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
|
||
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
Completed |
NCT04445337 -
Stellate Ganglion Blockade in COVID-19 Positive Patients
|
N/A | |
Active, not recruiting |
NCT04374487 -
Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
|
Phase 2 | |
Completed |
NCT04403243 -
COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04375644 -
Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
|
||
Completed |
NCT04394078 -
Impact of COVID-19 Pandemic on Depression and Quality of Life
|
||
Recruiting |
NCT04407923 -
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
|
||
Completed |
NCT04426305 -
Community Health Workers Against COVID19
|
N/A | |
Withdrawn |
NCT04519411 -
Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure
|
N/A | |
Recruiting |
NCT04492514 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation
|
Phase 2 | |
Completed |
NCT04403828 -
Impact of COVID-19 on Personal Protection Among Dentist in Egypt
|
||
Completed |
NCT04399980 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 |